Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation

Blood

Volumn 100, Issue 12, 2002, Pages 3908-3918

  Rocha, Vanderson ^a,b,c   Franco, Rendrik F ^a,b   Porcher, Raphaël ^a,b   Bittencourt, Henrique ^a,b   Silva Jr , Wilson A ^a,b   Latouche, Aurelien ^a,b   Devergie, Agnès ^a,b   Espérou, Hélène ^a,b   Ribaud, Patricia ^a,b   Socié, Gérard ^a,b   Zago, Marco Antonio ^a,b   Gluckman, Eliane ^a,b  

^a Bone Marrow Transplant Unit   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN; FC RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LECTIN; LYMPHOTOXIN; MANNOSE BINDING PROTEIN; METHOTREXATE; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CHRONIC LEUKEMIA; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENOTYPE; GRAFT VERSUS HOST REACTION; HAZARD ASSESSMENT; HLA MATCHING; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; VIRUS INFECTION;

EID: 0036892525     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1033     Document Type: Article

References (67)

1. Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943-3948.
2. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001;72:699-706.
3. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996;335:1941-1949.
4. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher D. Association between FcßRIIa-R131 allotype and bacteremic pneumococcal pneumonia. J Clin Infect Dis. 2000;30:25-28.
5. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease: Meningococcal Research Group. Lancet. 1999;353:1049-1053.
6. Kwiatkowski D. Genetic dissection of the molecular pathogenesis of severe infection. Intensive Care Med. 2000;26:89-97.
7. Klebanoff SJ. Myeloperoxidase contribution to the microbicidal activity of intact leukocytes. Science. 1970;169:1095-1097.
8. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001-5003.
9. Schabath MB, Spitz MR, Hong WK, et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 2002;37: 35-40.
10. Morariu-Zamfir R, Rocha V, Devergie A, et al. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukemia. Bone Marrow Transplant. 2001;27:575-580.
11. Miller AS, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16: 1215-1218.
12. Padovani JC, Pazin-Filho A, Simoes MV, MarinNeto JA, Zago MA, Franco RF. Gene polymorphisms in the TNF locus and the risk of myocardial infarction. Thromb Res. 2000;100:263-269.
13. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest. 1998;102: 2146-2155.
14. Fishman D, Faulds G, Jeffrey R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:13691376.
15. 131 ligandbinding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods. 1996;199:55-59.
16. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-1070.
17. Hessner MJ, Curtis BR, Endean DJ, Aster RH. Determination of neutrophil antigen gene frequencies in five ethnic groups by polymerase chain reaction with sequence-specific primers. Transfusion. 1996;36:895-899.
18. Voraberger G, Schafer R, Stratowa C. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5′-regulatory region: Induction by cytokines and phorbol ester. J Immunol. 1991;147:2777-2786.
19. American Society of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
20. Lossos IS, Breuer R, Or R, et al. Bacterial pneumonia in recipients of bone marrow transplantation. Transplantation. 1995;60:672-678.
21. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin SA, eds. Proceedings of the Fourth International Cytomegalovirus Workshop: Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Paris, France: Elsevier Science Publishers BV; 1993:233-237.
22. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34:563-571.
23. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
24. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57:267-276.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA. 1999;94:496-509.
26. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195-3199.
27. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferongamma, interleukin-10, transforming growth factor-beta1 and tumor necrosis factor-alpha genes: A technical report. Transplant Immunol. 1998;6: 193-199.
28. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor locus: A Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991;173:209228.
29. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-2147.
30. El-Omar EM, Carrington M, Chow WH, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature. 2001;412:99.
31. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1 beta production in vitro. Scand J Immunol. 1998;47:195-198.
32. Andus T, Daig R, Vogl D, et al. Imbalance of the interleukin 1 system in colonic mucosa - Association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2. Gut. 1997;41: 651-657.
33. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995;99:303-310.
34. Tountas NA, Casini-Raggi V, Yang H, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology. 1999;117:806-813.
35. Behar E, Chao NJ, Hiraki DD, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med. 1996;334:286-291.
36. Balduini CL, Frassoni F, Noris P, et al. Donorrecipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. Br J Haematol. 2001;114:951-953.
37. Fernandez-Reyes D, Craig AG, Kyes SA, et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet. 1997; 6:1357-1360.
38. Haagen IA, Geerars AJG, Clarck MR, van de Winkel JGJ. Interaction of human monocyte Fcγ receptors with rat IgG2b: A new indicator for the FcγRIIa (R-H131) polymorphism. J Immunol. 1995;154:1852-1860.
39. Bredius RGM, Fijen CAP, de Hass M, et al. Role of the neutrophil Fcγ IIa (CD32) and FcγIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. 1994;83:624-630.
40. Salmon JE, Edberg JC, Brogle NL, Kimberley RP. Allelic polymorphisms of human Fcγ receptor IIa and Fcγ receptor IIIb independent mechanisms for differences in human phagocyte function. J Clin Invest. 1992;89:1274-1281.
41. Ravetch JV, Perussia B. Alternative membrane forms of FcγRIII (CD16) on human natural killer cells and neutrophils: Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989;170:481-497.
42. Koene HR, de Hass M, Kleijer M, Roos D, von dem Borne AEGK. NA-phenotype dependent differences in neutrophil Fcγ receptor IIIb expression cause differences in plasma levels of soluble Fcγ receptor III. Br J Haematol. 1996;93:235-241.
43. Turner MW. Mannose binding lectin: The pluripotent molecule of the innate system. Immunol Today. 1996;17:532-540.
44. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannose-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods. 2000;241:33-42.
45. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid, hormone-retinoic acid response element. J Biol Chem. 1996;271:14412-14420.
46. Hill AVS. Immunogenetics and genomics. Lancet. 2001;357:2037-2041.
47. Grumet FC, Hiraki DD, Brown BWM, et al. CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant. 2001;7:503512.
48. van der Pol WL, van de Winkel JGJ. IgG receptor polymorphisms: Risk factors for disease. Immunogenetics. 1998;48:222-232.
49. Wilson ME, Kalmar JR. FcγRIIa (CD32): A potential marker defining susceptibility to localized juvenile periodontitis. J Peridontol. 1996;67:323331.
50. Ravanel K, Castelle C, Defrance T, Wild TF, Charron D, Lotteau V, Rabourdin-Combe C. Measles virus nucleocapsid protein binds to FcγII and inhibits human B cell antibody production. J Exp Med. 1997;186:269-278.
51. Gavin A, Hogarth PM. The involvement of human FcγR in altered immunity and disease. In: van de Winkel JGJ, Capel PJA, eds. Human IgG Fc Receptors. Heidelberg, Germany: Springer; 1996: 195-225.
52. Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, Richar WJ. Myeloperoxidase deficiency: Prevalence and clinical significance. Ann Intern Med. 1981;95:293-301.
53. Eiserich JP, Hristova M, Cross CE, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998; 391:393-397.
54. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? Acta Haematol. 2000;104:10-15.
55. Aratani Y, Kura F, Watanabe H, et al. Differential host susceptibility to pulmonary infections with bacteria and fungi in mice deficient in myeloperoxidase. J Infect Dis. 2000;182:1276-1279.
56. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood. 1997;90:2730-2737.
57. Meisel P, Krause T, Cascorbi I, et al. Gender- and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles. Gene Immunol. 2002;3:102-106.
58. Barry SM, Johnson MA, Janossy G. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant. 2000;26:591-597.
59. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood. 2002;99:3524-3529.
60. Huizinga TWJ, de Haas M, Kleijer M, et al. Biallelic neutrophil NA-antigen system is associated with a polymorphism on the phospho-inositol-linked Fcγ receptor III (CD16). Blood. 1990;75: 213-217.
61. Bux J. Granulocyte immunology. Wien Klin Wochenschr. 2001;21:799-805.
62. Tazzari PL, Rondelli D, Re F, et al. Antibodies reactive with neutrophils following allogeneic haematopoietic stem cell transplantation. Eur J Haematol. 1999;62:57-62.
63. Klumpp TR, Herman JH, Schnell MK, Golberg SL, Mangan KF. Association between antibodies reactive with neutrophils, rate of neutrophil engraftment and incidence of post-engraftment neutropenia following BMT. Bone Marrow Transplant. 1996;18:559-564.
64. Huizinga TWJ, de Haas M, van Oers MHJ, et al. The plasma concentration of soluble Fc-gamma Rill is related to the production of neutrophils. Br J Haematol. 1994;87:459-463.
65. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic transplants. Br J Haematol. 2001;113:807-813.
66. Hill GR, Teskima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft-versus leukemia. J Clin Invest. 1999;104:459-467.
67. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941-3946.